NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

Continue Learn More X

Home » News » Company News » Fractyl gets FDA breakthrough device status for Revitam DMR to treat type 2 diabetes » an-injection-5024607_640

Fractyl gets FDA breakthrough device status for Revitam DMR to treat type 2 diabetes

NS Medical Devices is using cookies

Fractyl is currently recruiting patients in the REVITA-T2Di trial. (Credit: dorofeevajana from Pixabay)

Related Article

Biggest players in the global wound care market

RECOMMENDED COMPANIES

MOST READ

Scopio Labs gets FDA nod for digital bone marrow aspirate application

Viz.ai, NICO collaborate on improving intracerebral hemorrhage outcomes

Outset Medical and U.S. Renal Care partner to expand home haemodialysis in US

FDA classifies Boston Scientific’s recall of Obsidio Embolic as most serious

Xstim secures FDA approval for spine fusion stimulator

Recommended Whitepaper